Phase II dose titration study of regorafenib for patients with unresectable metastatic colorectal cancer who are progressed after standard chemotherapy
收藏NIAID Data Ecosystem2026-03-09 收录
官方服务：
资源简介：
Interventions: Regorafenib 40 mg tablets Regorafenib 120 mg od po. 3weeks on/1 week off Patients will continue study treatment until disease progression Primary outcome(s): Disease control rate Study Design: Single arm Non-randomized
创建时间：
2015-09-15
